Terms: = Pancreatic cancer AND ACVR1, SKR1, 90, ENSG00000115170, Q04771, ACVRLK2, FOP, ALK2, ACTRI AND Treatment
1497 results:
1. Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of pancreatic Carcinomas: In Search of Therapeutic Targets.
Faber EB; Krause HB; Amin K; Walker P; Hosein PJ; Shields AF; Lenz HJ; Prakash A; Goel S; Oberley M; Malleo G; Luchini C; Hwang J; Florou V; Garrido-Laguna I; Lou E
JCO Precis Oncol; 2024 May; 8():e2300595. PubMed ID: 38723231
[TBL] [Abstract] [Full Text] [Related]
2. Targeting KRAS in pancreatic cancer.
Stickler S; Rath B; Hamilton G
Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056
[TBL] [Abstract] [Full Text] [Related]
3. The effect of metabolism-related lifestyle and clinical risk factors on digestive system cancers in East Asian populations: a two-sample Mendelian randomization analysis.
Cai X; Li X; Liang C; Zhang M; Dong Z; Yu W
Sci Rep; 2024 Apr; 14(1):9474. PubMed ID: 38658636
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial.
Xu L; Chen J; Liu C; Song X; Zhang Y; Zhao H; Yan S; Jia W; Wu Z; Guo Y; Yang J; Gong W; Ma Y; Yang X; Gao Z; Zhang N; Zheng X; Li M; Su D; Chen M
BMC Med; 2024 Apr; 22(1):172. PubMed ID: 38650037
[TBL] [Abstract] [Full Text] [Related]
5. Assessment of disease control rate and safety of sorafenib in targeted therapy for advanced liver cancer.
Zeng D; Yu C; Chen S; Zou L; Chen J; Xu L
World J Surg Oncol; 2024 Apr; 22(1):93. PubMed ID: 38605359
[TBL] [Abstract] [Full Text] [Related]
6. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.
Wasko UN; Jiang J; Dalton TC; Curiel-Garcia A; Edwards AC; Wang Y; Lee B; Orlen M; Tian S; Stalnecker CA; Drizyte-Miller K; Menard M; Dilly J; Sastra SA; Palermo CF; Hasselluhn MC; Decker-Farrell AR; Chang S; Jiang L; Wei X; Yang YC; Helland C; Courtney H; Gindin Y; Muonio K; Zhao R; Kemp SB; Clendenin C; Sor R; Vostrejs WP; Hibshman PS; Amparo AM; Hennessey C; Rees MG; Ronan MM; Roth JA; Brodbeck J; Tomassoni L; Bakir B; Socci ND; Herring LE; Barker NK; Wang J; Cleary JM; Wolpin BM; Chabot JA; Kluger MD; Manji GA; Tsai KY; Sekulic M; Lagana SM; Califano A; Quintana E; Wang Z; Smith JAM; Holderfield M; Wildes D; Lowe SW; Badgley MA; Aguirre AJ; Vonderheide RH; Stanger BZ; Baslan T; Der CJ; Singh M; Olive KP
Nature; 2024 May; 629(8013):927-936. PubMed ID: 38588697
[TBL] [Abstract] [Full Text] [Related]
7. Multiscale and multiperception feature learning for pancreatic lesion detection based on noncontrast CT.
Yan T; Tang G; Zhang H; Liang L; Ma J; Gao Y; Zhou C; Li S
Phys Med Biol; 2024 May; 69(10):. PubMed ID: 38588676
[No Abstract] [Full Text] [Related]
8. A meta-analysis on the efficacy of endoscopic ultrasonography for treatment of pancreatic cancer.
Xuan M; Li N; Wu C
Clinics (Sao Paulo); 2024; 79():100348. PubMed ID: 38552386
[TBL] [Abstract] [Full Text] [Related]
9. Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis.
Cigrovski Berkovic M; Coppola A; Sesa V; Mrzljak A; Lai Q
World J Gastroenterol; 2024 Feb; 30(7):759-769. PubMed ID: 38515954
[TBL] [Abstract] [Full Text] [Related]
10. Prophylactic abdominal drainage after distal pancreatectomy (PANDORINA): an international, multicentre, open-label, randomised controlled, non-inferiority trial.
van Bodegraven EA; Balduzzi A; van Ramshorst TME; Malleo G; Vissers FL; van Hilst J; Festen S; Abu Hilal M; Asbun HJ; Michiels N; Koerkamp BG; Busch ORC; Daams F; Luyer MDP; Ramera M; Marchegiani G; Klaase JM; Molenaar IQ; de Pastena M; Lionetto G; Vacca PG; van Santvoort HC; Stommel MWJ; Lips DJ; Coolsen MME; Mieog JSD; Salvia R; van Eijck CHJ; Besselink MG;
Lancet Gastroenterol Hepatol; 2024 May; 9(5):438-447. PubMed ID: 38499019
[TBL] [Abstract] [Full Text] [Related]
11. Polycyclic Aromatic Hydrocarbons and pancreatic cancer: An Analysis of the Blood Biomarker,
Nguyen S; Carlson H; Yoder A; Bamlet WR; Oberg AL; Petersen GM; Carmella SG; Hecht SS; Jansen RJ
Nutrients; 2024 Feb; 16(5):. PubMed ID: 38474816
[TBL] [Abstract] [Full Text] [Related]
12. Feasibility of proton dosimetry overriding planning CT with daily CBCT elaborated through generative artificial intelligence tools.
Rossi M; Belotti G; Mainardi L; Baroni G; Cerveri P
Comput Assist Surg (Abingdon); 2024 Dec; 29(1):2327981. PubMed ID: 38468391
[TBL] [Abstract] [Full Text] [Related]
13. Impact of a non-therapeutic laparotomy in patients with locally advanced pancreatic cancer treated with induction (m)FOLFIRINOX: Trans-Atlantic pancreatic Surgery (TAPS) Consortium study.
Theijse RT; Stoop TF; Janssen QP; Prakash LR; Katz MHG; Doppenberg D; Tzeng CD; Wei AC; Zureikat AH; Groot Koerkamp B; Besselink MG
Br J Surg; 2024 Mar; 111(3):. PubMed ID: 38456678
[TBL] [Abstract] [Full Text] [Related]
14. Neoadjuvant Peptide Receptor Radionuclide Therapy in a Rare Case of Pediatric Primary Hepatic Gastrinoma.
Mahato S; Aggarwal P; Thunga C; Sood A; Kanojia RP; Nada R; Lal SB
Clin Nucl Med; 2024 Apr; 49(4):e161-e163. PubMed ID: 38427960
[TBL] [Abstract] [Full Text] [Related]
15. Transarterial Chemoembolization with Epirubicin-Loaded Microspheres for Hepatocellular Carcinoma: A Prospective, Single-Arm, Multicenter, Phase 2 Study (STOPPER Trial).
Zhu HD; Li X; Sun JH; Zhu X; Liu ZY; Li HL; Lu J; Yan ZP; Shao GL; He XF; Chao M; Lu LG; Zhong BY; Li R; Zhang Q; Teng GJ
Cardiovasc Intervent Radiol; 2024 Mar; 47(3):325-336. PubMed ID: 38413420
[TBL] [Abstract] [Full Text] [Related]
16. Optimal extent of lymph node dissection for high-risk gastric cancer stratified by a national clinical database risk calculator.
Kuroda K; Miki Y; Kasashima H; Yoshii M; Fukuoka T; Tamura T; Shibutani M; Toyokawa T; Lee S; Maeda K
World J Surg; 2024 May; 48(5):1198-1208. PubMed ID: 38391091
[TBL] [Abstract] [Full Text] [Related]
17. [Short-term outcomes of the TRIANGLE operation after neoadjuvant chemotherapy in locally advanced pancreatic cancer].
Xu D; Tu M; Zhang K; Wu PF; Lyu N; Wang QQ; Yin J; Wu Y; Lu ZP; Chen JM; Xi CH; Wei JS; Guo F; Miao Y; Jiang KR
Zhonghua Wai Ke Za Zhi; 2024 Feb; 62(2):147-154. PubMed ID: 38310383
[No Abstract] [Full Text] [Related]
18. [Tolerability and Outcome of Neoadjuvant GS Therapy for Resectable pancreatic cancer].
Yamashita M; Shimizu J; Sato Y; Noma T; Hagihara K; Yanagimoto Y; Suzuki Y; Ikenaga M; Kawase T; Imamura H; Akagi K; Iwasawa S; Tomita N
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1411-1413. PubMed ID: 38303291
[TBL] [Abstract] [Full Text] [Related]
19. Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot Study.
Trautwein NF; Hinterleitner C; Kiefer LS; Singer S; Mattern S; Schwenck J; Reischl G; Sipos B; Lauer UM; Dittmann H; Zender L; la Fougère C; Hinterleitner M
Clin Nucl Med; 2024 Mar; 49(3):207-214. PubMed ID: 38271237
[TBL] [Abstract] [Full Text] [Related]
20. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
[TBL] [Abstract] [Full Text] [Related]
[Next]
